Combining thiopurine with partial enteral nutrition promotes complete mucosal healing in pediatric Crohn's disease
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Thiopurines and partial enteral nutrition (TP/PEN) significantly improved mucosal healing in pediatric Crohn's disease patients. While relapse rates were similar, TP/PEN offers a viable treatment option for achieving remission.
Area Of Science
- Pediatric Gastroenterology
- Inflammatory Bowel Disease Research
- Clinical Nutrition
Background
- Partial enteral nutrition (PEN) combined with thiopurines (TP) is a standard maintenance therapy for mild-to-moderate pediatric Crohn's disease (CD).
- Limited evidence exists on the efficacy of TP/PEN for pediatric CD.
- This study evaluates TP/PEN versus PEN alone in pediatric CD patients.
Purpose Of The Study
- To assess the non-relapse rate in pediatric CD patients treated with TP/PEN versus PEN-only.
- To evaluate the complete mucosal healing rate in pediatric CD patients receiving TP/PEN versus PEN-only.
- To determine the long-term efficacy of TP/PEN in managing pediatric Crohn's disease.
Main Methods
- Retrospective observational study of 39 pediatric CD patients.
- Patients categorized into TP/PEN and PEN-only groups.
- Primary outcome: relapse-free rate (defined by PCDAI, SES-CD, Lewis score, CRP). Secondary outcome: complete mucosal healing (SES-CD score 0) at 12-24 months.
Main Results
- No statistically significant difference in non-relapse rates between TP/PEN and PEN-only groups.
- Significantly higher complete mucosal healing rates in the TP/PEN group (33.3%) compared to the PEN-only group (5.5%) at 12-24 months (p < 0.05).
- TP/PEN demonstrated superior efficacy in achieving mucosal healing.
Conclusions
- TP/PEN is a viable treatment option for pediatric patients with mild-to-moderate Crohn's disease.
- The combination therapy shows promise in achieving complete mucosal healing.
- Further research may explore optimal therapeutic strategies in pediatric CD management.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...